Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective.
Orozco-Leal G, Johnson EE, Hosseinijebeli S, Robinson T, Homer T, Eastaugh CH, Richmond C, Tanner L, Meader N, Kenny R, Wallace SA, Rice S. Orozco-Leal G, et al. Pharmacoeconomics. 2024 Feb;42(2):133-136. doi: 10.1007/s40273-023-01328-w. Epub 2023 Nov 20. Pharmacoeconomics. 2024. PMID: 37985576 No abstract available.
Economic evaluations of interventions to prevent and control health-care-associated infections: a systematic review.
Rice S, Carr K, Sobiesuo P, Shabaninejad H, Orozco-Leal G, Kontogiannis V, Marshall C, Pearson F, Moradi N, O'Connor N, Stoniute A, Richmond C, Craig D, Allegranzi B, Cassini A. Rice S, et al. Among authors: orozco leal g. Lancet Infect Dis. 2023 Jul;23(7):e228-e239. doi: 10.1016/S1473-3099(22)00877-5. Epub 2023 Mar 28. Lancet Infect Dis. 2023. PMID: 37001543 Review.
Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Orozco Leal G, Armstrong N, Kernohan A, Ahmadu C, Coughlan D, McDermott K, Duffy S, O'Meara S, Robinson T, Vale L, Kleijnen J. Orozco Leal G, et al. Pharmacoeconomics. 2023 Jul;41(7):741-750. doi: 10.1007/s40273-023-01259-6. Epub 2023 Mar 23. Pharmacoeconomics. 2023. PMID: 36952138 Free PMC article. Review.
Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT.
Heer R, Lewis R, Duncan A, Penegar S, Vadiveloo T, Clark E, Yu G, Mariappan P, Cresswell J, McGrath J, N'Dow J, Nabi G, Mostafid H, Kelly J, Ramsay C, Lazarowicz H, Allan A, Breckons M, Campbell K, Campbell L, Feber A, McDonald A, Norrie J, Orozco-Leal G, Rice S, Tandogdu Z, Taylor E, Wilson L, Vale L, MacLennan G, Hall E. Heer R, et al. Among authors: orozco leal g. Health Technol Assess. 2022 Oct;26(40):1-144. doi: 10.3310/PLPU1526. Health Technol Assess. 2022. PMID: 36300825 Free PMC article. Clinical Trial.
A Randomized Trial of PHOTOdynamic Surgery in Non-Muscle-Invasive Bladder Cancer.
Heer R, Lewis R, Vadiveloo T, Yu G, Mariappan P, Cresswell J, McGrath J, Nabi G, Mostafid H, Lazarowicz H, Kelly J, Duncan A, Penegar S, Breckons M, Wilson L, Clark E, Feber A, Orozco-Leal G, Tandogdu Z, Taylor E, N'Dow J, Norrie J, Ramsay C, Rice S, Vale L, MacLennan G, Hall E. Heer R, et al. Among authors: orozco leal g. NEJM Evid. 2022 Oct;1(10):EVIDoa2200092. doi: 10.1056/EVIDoa2200092. Epub 2022 Sep 2. NEJM Evid. 2022. PMID: 38319866 Clinical Trial.